Mono Pharmacare Ltd vs Onyx Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Mono Pharmacare Ltd is ₹ 12.5 as of 05 May 15:30 . The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 .The P/E Ratio of Onyx Biotec Ltd is 0 as of March 2023 . The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Onyx Biotec Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 years .

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

FAQs for the comparison of Mono Pharmacare Ltd and Onyx Biotec Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Onyx Biotec Ltd?

Market cap of Mono Pharmacare Ltd is 22 Cr while Market cap of Onyx Biotec Ltd is 62 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Onyx Biotec Ltd?

The stock performance of Mono Pharmacare Ltd and Onyx Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Onyx Biotec Ltd?

As of May 5, 2026, the Mono Pharmacare Ltd stock price is INR ₹12.5. On the other hand, Onyx Biotec Ltd stock price is INR ₹34.7.

How do dividend payouts of Mono Pharmacare Ltd and Onyx Biotec Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Onyx Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.